We isolated the MAL (T-lymphocyte maturation associated protein) gene from differentially expressed products of esophageal epithelium relative to esophageal carcinoma tissues. The Mal protein has been demonstrated as being a component of the protein machinery for apical transport in epithelial polarized cells. In this study, we describe the reduced expression of MAL in all 39 cases of esophageal carcinoma tested and 60 other human carcinomas. MAL gene transcription was induced in three out of 13 esophageal carcinoma cell lines by treatment with the demethylating agent 5-aza-2 0 -deoxycytidine (DAC), and in nine additional cell lines by simultaneous treatment with trichostatin A, an inhibitor of deacetylation, and DAC. We established a stable MAL gene transfectant whose expression was regulated by subcutaneous doxycycline injection in nude mice. Tumor growth was suppressed in cells expressing TE3-MAL compared with TE3 parent cells or cells not expressing TE3-MAL with doxycycline injection (20 lg/body) (Po0.01). Additionally, the TE3-MAL transfectant cells exhibited decreased cellular motility, a G1/S transition block and increased levels of apoptosis, concomitant with increased expression of Fas receptor in vitro. The apoptotic staining in MALexpressing tumors was confirmed by TUNEL assay. Therefore, we conclude that expression of MAL was frequently decreased or diminished in gastrointestinal tract cancers, and that Mal expression confers reduced tumorigenicity in vivo to tumor TE3 cells through the induction of apoptosis via the Fas signaling pathway.
Introduction
In the previous studies, we have used techniques of subtractive cDNA cloning and differential display to compare genes expressed in paired tumor/normal samples of gastrointestinal tract cancers, with the goal of identifying prognostic markers. So far, we have identified cistatin B, and G protein gamma 7 by differential display as candidate suppressor genes in esophageal cancer tissues. In addition, hepatocyte-derived growth factor gene was highly expressed in established radioresistant esophageal cancer cells (Matsuyama et al., 2001) . In the present study, the expression of MAL (T-lymphocyte maturation associated) gene was found to be extinguished in esophageal carcinoma and other gastrointestinal cancer tissues relative to the corresponding normal epithelium.
The MAL gene is located on the proximal long arm of the human chromosome 2, region cen-q13 where neither genomic alterations nor cancer suppressor genes have been identified thus far, although there have been a few reports describing large homozygous deletions at 2q13 in juvenile nephronophthisis (Konrad et al., 1996; Saunier et al., 2000) and frequent deletions in prostate cancer (Dong, 2001) .
The MAL gene was originally identified by Alonso and Weissman (1987) during a search for genes differentially expressed during T-cell development. The MAL gene was predicted to encode a 17-kDa integral membrane protein, referred to as Mal. More recently, Mal was identified as a component of glycolipidenriched membrane microdomains or rafts, which are membranes characterized by their resistance to detergent solubilization, in T lymphocytes, epithelial MadinDarby canine kidney cells and myelin-forming cells (Kim et al., 1995; Martin-Belmonte et al., 1998; Millan and Alonso, 1998) . MAL has been demonstrated to play an essential role as component of the protein machinery for apical transport of membrane and secretory proteins (Cheong et al., 1999; Puertollano and Alonso, 1999; Martin-Belmonte et al., 2000 , 2001 . Based on the ability of MAL to induce extensive raft vesiculation (Puertollano et al., 1997), a role for MAL in the formation of the apical transport carriers was proposed (Puertollano et al., 2001) .
Since the MAL gene is strongly expressed in normal esophageal epithelial cells but becomes extinguished in esophageal carcinoma, as determined by the differential display technique, we examined the mechanism of MAL gene downregulation and examined the effect of Mal expression in carcinoma TE3 cells, an esophageal cancer-derived cell line. Our results show that ectopic expression of MAL in TE3 cells repressed the formation of tumors induced by TE3 cells in nude mice, inhibited cell motility and produced apoptosis by the Fas pathway. The present study is the first report of Mal as a tumor suppressor protein.
Results

Expression of MAL mRNA in esophageal cancers
Differential display experiments suggested that MAL expression was reduced or absent in esophageal cancers compared to normal cells. To confirm this finding, we prepared RNA from cancer cell lines and primary tumors and assessed the level of MAL mRNA expression by RT-PCR relative to the expression of a housekeeping gene, GAPDH. Figure 1a shows the expression of the MAL gene in representative samples from normal esophageal epithelium. It is of special note that essentially absent expression of the MAL gene was found in all the 39 cases of esophageal cancer tested. In addition, no expression of the MAL gene was detected by RT-PCR assays in 20 representative esophageal carcinoma cell lines (Figure 1a ). Other human carcinoma cell lines and carcinoma tissue samples analysed showed also the absence of MAL gene (60 samples).
Why is MAL not expressed in carcinoma?
Since we had no reason to suppose that expression of the MAL gene was extinguished in cancers by mutations or deletions, we first considered the possibility that promoter methylation could be involved in its downregulation. Carcinoma cells were treated with 5-aza-2 0 -deoxycytidine (DAC) to induce demethylation. Efficiency of the DAC treatment was confirmed by use of known methylation-regulated genes such as MAGE (Mori et al., 1996) (Figure 1b, left) . Expression of the MAL gene was induced by DAC in three, TE1, TE3 and TE5, out of 13 esophageal carcinoma cell lines analysed (Figure 1b, right) . Figure 1c shows four examples of the induction of MAL expression simultaneous treatment with trichostatin A (TSA), an inhibitor of deacetylation, and DAC. The MAL gene was not transcriptionally reactivated with TSA alone in tumor cells whereas the combined treatment with DAC and TSA can upregulate expression of the MAL gene in 12 out of 13 cell lines examined (Table 1 ). The TE7 cell line showed baseline expression of MAL mRNA without TSA and DAC treatment. These data are summarized in Table 1 . We next compared the effect of exogenous expression of MAL in the apoptotic process. The expression of the Fas antigen was reduced in transfected TE3 cells expressing exogenous Mal (12.8%) compared with that Positive bands appeared after RT-PCR amplification of cDNAs from most normal tissues, but were absent or substantially reduced in cDNA from 15 tumor tissue specimens. There was no MAL expression in 10 TE series cell lines and 10 KYSE series cell lines. Both left ends showed the MAL expression in Jurkat cells as a positive control. Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) mRNA was an internal control, (b,c), Induction of MAL gene expression by DAC and TSA treatment. We used the conditions for DAC treatment that induce expression of MAGE3 in KYSE170 and COLO205. The letter C shows a control cell line, and KYSE170 and COLO205 did not express the MAL gene without induction, as described elsewhere (Mori et al., 1996) (b, left) ; three esophageal cancer cell lines, TE1, TE3 and TE5 showed MAL expression only after DAC treatment (b, right). (c) Four examples of the induction of MAL expression by TSA and DAC treatment (see Table 1 ). The Roman numerals I, II and III indicate conditions for TSA and DAC treatment. TE1 and TE3 show MAL expression after both treatments; on the other hand, TE4 and TE14 express MAL only after DAC treatment. (Figure 6b ). These findings may indicate that TE3 esophageal cancer cells expressing MAL undergo apoptosis through the Fas pathway more rapidly and frequently than the TE3 parental cells, although the two cell types did not show differences in performing 
Yes ---a I, DAC 100 nm (24 h), TSA 300 nm (24 h); II, DAC 500 nm (24 h), TSA 1000 nm (24 h); III, DAC 1000 nm (48 h), TSA 500 nm (24 h) Similarly, the two cell types, the TE3 parent cell and the TE3-MAL expressing clone did not show any difference in the levels of apoptosis-related proteins, such as p53, Bcl2, Bax and Lck proteins as assayed by Western blotting (data not shown).
By use of the TUNEL assay, we confirmed the existence of apoptosis at day 16 in resected specimen of the tumor on nude mouse inoculated with TE3 cells expressing Mal, whereas few apoptotic cells were observed in mice inoculated with the transfectant under conditions of absence of MAL expression ( Figure 7 ).
Discussion
Using differential display techniques, we observed MAL as a gene that is severely reduced in expression in esophageal carcinomas relative to normal esophageal epithelium. The Mal protein is known to be a proteolipid component of the detergent-resistant membrane microdomains or lipid rafts in a restricted pattern of cell types including polarized epithelial cells, myelinforming cells and T lymphocytes. Mal appears to act as machinery for raft remodeling during differentiation in T cell and for apical transport in epithelial cells (Millan et al., 1997) . There was no previous evidence of a correlation between MAL expression and human epithelial malignancies. In the current study, we have discovered a close correlation of Mal protein expression with carcinogenesis and/or progression of human cancers, especially in esophageal cancer, a neoplasm with high malignant potential (Sugimachi et al., 1988) .
Although Tugores et al. (1997) reported that engineered deletions in the MAL promoter region affected transcriptional inactivation, no genetic alterations have been observed in the MAL genomic region. Moreover, we deduced that MAL promoter methylation had occurred in three of 13 esophageal cancer cell lines and trichostatin-upregulated MAL expression in nine more cell lines. As Cameron et al. (1999) described for MLH1, TIMP3, CDKN2B (INK4B, p15) and CDKN2A (INK4, p16), we speculate that DNA methylation and histone deacetylation in the MAL promoter to act as synergistic controls for the silencing of the MAL gene in cancer. However, we have not yet determined whether the MAL gene may be modulated by other mechanisms, such as deletion, mutation or other aberrations in cancer.
According to the functional assays performed, exogenous expression of Mal in carcinoma TE3 cells causes Figure 4 Motility and invasion in matrigel. In clone #12, the average number of cells penetrating through the chamber for TE3 parent cells (262) or TE3-MAL nonexpressing cells (Dox 2 mg) (251) was significantly greater than for TE3-MAL expressing cells (Dox 0 mg) (108) (Po0.01). In clone #22, the number of penetrating cells was significantly lower for TE3-MAL expressing cells (Dox 0 mg) (137) than for the TE3 parent cells or TE3-MAL nonexpressing cells (Dox 2 mg) (259) (Po0.05). Thus, MAL expression reduced cellular motility and the ability to penetrate membranes reduced cell motility in vitro and diminished tumorigenicity in vivo. The effect on tumorigenicity is probably a result of the notable induction of apoptosis caused by MAL expression as shown in Figures 5 and 6 . The apoptosis in the Mal-expressing tumor was confirmed by the TUNEL assay (Figure 7) . We observed increased expression of Fas receptor (Figure 6a ) independent of p53, Bax, Bcl2 and Lck as examined by Western blot analysis (data not shown), suggesting that the induction of apoptosis by Mal protein is intimately involved with the Fas signaling pathway. However, further study is required to clarify the mechanism of the induction of apoptosis through Fas in these cells.
In conclusion, we have discovered that the expression of Mal, a component of the apical sorting machinery (Puertollano and Alonso, 1999) , is remarkably reduced, sometimes because of DNA methylation, in human esophageal cancers as well as in various other epithelial cancers. The antitumor effect of Mal was confirmed in vitro and in vivo. In MAL-expressing esophageal cancer cells, apoptosis occurred via the Fas signaling pathway. These findings suggest that Mal may become an excellent target molecule for cancer gene therapy.
Materials and methods
Tumor source and cell lines
Primary tumor tissue was collected from patients with esophageal (39), colorectal (20), gastric (20) and breast carcinoma (20) at the Department of Surgery, Saitama Prefectural Hospital, Saitama; the Department of Surgery, Medical Institute of Bioregulation Hospital, Kyushu University; and the Department of Surgery, Oita Prefectural Hospital. Regarding the clinicopathologic characteristics in 39 esophageal cancer cases, the number of male and female patients was 32 and 7, respectively. Regarding histological classification, there were 31 cases of well or moderately squamous cell cancer, four cases of undifferentiated squamous cell cancer and four other cases. Regarding depth of tumor invasion, 14 cases were restricted to within the adventitia, and 25 invaded beyond it. Regarding lymph node metastasis, 13 cases were absent, while 26 cases were positive. Regarding lymphatic invasion, three were absent and 36 were positive. Regarding vascular invasion, seven were absent and 32 were present. Fresh tumor tissue was obtained after surgical resection and stored immediately at À801C until used for DNA and RNA analysis.
A total of 10 esophageal carcinoma cell lines ( Figure 1a ) were evaluated for expression of the MAL gene. We cultured the TE series from Nishihira et al. (1993) , the Second Department of Surgery, Tohoku University School of Medicine and the KYSE series from Shimada et al. (1992) , the First Department of Surgery, Faculty of Medicine, Kyoto University, Japan. Cell lines were grown in RPMI 1640 in a 5% CO 2 incubator at 371C. KYSE150, KATOIII, COLO201 and MCF7 cell lines were also analysed.
cDNA preparation from tissue specimens Total RNA was extracted by the method of acid guanidinium thiocyanate/phenol/chloroform extraction (AGPC) (Mimori et al., 1997) . Total RNA (1 mg) was reverse transcribed into cDNA using oligo-dT primers.
Identification of the MAL gene as a differentially expressed gene
The differential display procedure was performed as in our previous study (Shiraishi et al., 1998) . In brief, cDNA was synthesized from 2.5 mg of total RNA extracted from five esophageal squamous carcinomas and matched normal tissue. The anchor primers gT15X were end-labeled with 32 Padenosine 5 0 -triphosphates (Amersham, Tokyo, Japan) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA). The conditions for PCR amplification were as Differences between TE3-MAL expressing clone #22 cells and TE3 parent cells (Po0.05), and TE3-MAL expressing clone #22 cells previously described (Shiraishi et al., 1998; Shibata et al., 1999) . The amplified cDNA product was electrophoresed on 6% sequencing gels and the bands of interest, those present only in products from normal tissue or only in products of cancer tissues, were cut out and heated at 941C. This mixture was reamplified and cloned by the TA cloning method (InVitrogen, San Diego, CA, USA), and cloned products were sequenced.
The sequence of one clone detected only in normal esophageal tissue was identical to the human MAL cDNA sequence (Genbank Accession #M15800) (Alonso and Weissman, 1987) , and was chosen for further study.
Primers for MAL gene detection
The MAL cDNA-specific primer sequences were CAG/TGG/ CTT/CTC/GGT/CTT/CAC, forward primer, and GTC/TTG/ CAT/CGT/GAT/GGT/GGC, reverse primer. The length of the amplified product is 307 bp, spanning from exons 1 to 3 of the MAL open-reading frame.
Analysis of MAL gene expression by semiquantitative RT-PCR assay
Amplification of MAL cDNA was performed in a total volume of 25 ml, which included 10 Â PCR buffer (100 mm Tris-HCl, pH 8.3, 500 mm KCl, 15 mm MgCl 2 , 1% Triton X-100), 25 mm dNTP (mixed dATP, dCTP, dGTP and dTTP, each 100 mm), 10 pmol forward and reverse MAL primers, and 1 U of Taq DNA polymerase (Promega, Madison, WI, USA). The reactions for MAL amplification were subjected to 24 cycles for 15 s at 941C, 30 s at 571C and 30 s at 721C in a thermal cycler 9600 (Roche, Japan). The amplification of GAPDH was performed by a protocol described elsewhere (Mori et al., 1995) . Amplified DNA fragments were electrophoresed on 1.5% agarose gels containing ethidium bromide with a DNA molecular weight marker for comparison. The amplified products were quantified by NIH Image Analysis, a software program for measurement of the amount of PCR product (Mori et al., 1996; Abbott et al., 1999; Wadler et al., 1999) . Statistical analyses for the significance of MAL mRNA expression in relation to clinicopathologic features were determined by Fisher's exact test.
Induction of gene expression by DAC TSA
Esophageal cancer cell lines were treated with 1 mm DAC for 72 h (Mori et al., 1996) , or DAC plus TSA, a specific inhibitor of histone deacetylase (Cameron et al., 1999) , to induce demethylation prior to assessment for induction of MAL expression. 
Transfection assay
The primers for amplification of full-length MAL cDNA were TCC/CAA/GCT/TGA/CGC/CAG/CAC/GCC, with a HindIII site, and TCA/TTA/AGC/CGC/AGG/AAT/TCT/ TGA/GCT/G, with an EcoRI site. The 511 bp full-lengthamplified MAL gene product was purified, cut with EcoRI and HindIII and ligated into the respective EcoRI and HindIII sites on the response vector pTRE2 (Clontech, CA, USA). Subsequent to the transfection of the regulatory plasmid pTet off into TE3 cells and clone selection, the MAL-pTRE2 plasmid was transfected into clones carrying pTet off using lipofectamine (Life Technologies, Inc., Rockville, MD, USA). Stably transfected colonies were selected and sequenced, and those expressing wild-type MAL were analysed further. The expression of Mal protein was assessed by Western blot analysis. Among 24 clones, clones #22 and #12, in which MAL expression was controlled by treatment with 2 mg doxycycline, were selected for further studies.
Western blot analysis
Cells (5 Â 10 7 -10 Â 10 7 ml) were washed with PBS and lysed for 20 min in 2 ml of 25 mm Tris-HCl pH 7.5, 150 mm NaCl, 5 mm EDTA, 1% Triton X-100 at 41C. The lysate was homogenized by passing the sample through a 22-gauge needle. Glycolipidenriched membrane (GEM) was isolated from the lysate by equilibrium centrifugation for Western blot analysis with anti-MAL 6D9 mAb. In brief, for immunoblot analysis, the GEM samples were subjected to SDS-PAGE in 15% acrylamide gels under reducing conditions and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). After blocking with 5% nonfat dry milk and 0.05% Tween-20 in PBS, blots were incubated with 6D9 mAb, used as culture supernatants diluted 1 : 2. After several washings, blots were incubated for 1 h with goat anti-mouse IgG (1 : 5000) coupled to a horseradish peroxidase, washed extensively, and developed using a chemiluminescence Western blotting kit (ECL, Amersham, Buckinghamshire, UK).
Apoptosis-related proteins were also detected using specific antibodies against p53 (Dako, Tokyo, Japan), Bcl2 (Dako, Tokyo, Japan), Bax (Dako, Tokyo, Japan) and Lck, a Src-like kinase (Dako, Tokyo, Japan).
Tumorigenicity assay
Tumor growth in nude mice was assayed by subcutaneous inoculation of 1 Â 10 7 cells of TE3 parent cells, TE3-MAL nonexpressing clone #22 cells with subcutaneous injection of DOX (20 mg/body) every 4 days, and TE3-MAL expressing clone #22 cells with subcutaneous injection of saline every 4 days as a control. After the inoculation, tumor size was measured in three dimensions. Three mice in each group were averaged to obtain the mean7s.d. Differences in tumor volumes were analysed by Student's t-test.
Micropore motility assay
The potential for invasion of MAL-transfected cells was determined by the Matrigel invasion assay. Polycarbonate membranes (8.0 mm pore size) of the upper chamber of 24-well transwell culture chambers were coated with Matrigel (BD BioCoatt Matrigelt Invasion Chamber, Becton Dickenson).
Subconfluent TE3 parent cells, TE3-MAL nonexpressing clone #22 cells, TE3-MAL expressing clone #22 cells and TE3-MAL expressing clone #12 cells were starved for 24 h and harvested with 0.05% trypsin containing 0.02% EDTA, washed twice with PBS, and resuspended at 5 Â 10 4 cells/ml in serum-free medium with 0.1% fraction V BSA. Tumor cell suspension (500 ml) was placed on the upper chamber, and the lower chamber was immediately filled with 750 ml of RPMI 1640 with 5% FBS as a chemoattractant. After 24 h of incubation at 371C, the membranes were stained with MayGrunwald and Giemsa solutions. In order to count the number of penetrated cells only, we wiped off cells on the surface of the Transwells coated with matrigel. Each experiment was performed in triplicate wells and repeated three times (Figure 4 ).
FACS and ELISA analyses
Cell cycle analysis was performed by means of DNA-PI binding and analyzed with an FACS flow cytometer. TE3 parent cells, TE3-MAL nonexpressing clone #22 cells and TE3-MAL expressing clone #22 cells (1 Â 10 6 ) were starved in serum-free medium for 48 h and then stimulated with DMEM including 10% FBS. After 18 h, cells were detached with 0.05% trypsin/0.02% EDTA and harvested by centrifugation, counted and prepared for cell cycle analysis. Cells were fixed in 70% ethanol, stained with PI (50 mg/ml) and analysed with an EPICS XL flow cytometer (Beckman Coulter Corp., Tokyo, Japan).
For cell proliferation analysis, ELISA was performed using the BrdU ELISA kit (Rosch Diagnostics Corp., Tokyo, Japan). TE3 parent cells, TE3-MAL nonexpressing clone cells and TE3-MAL expressing clone cells were starved in a 96-well plate for 72 h in DMEM, including 3% FBS, and then stimulated with EGF (Sigma-Aldrich Corp., St Louis, MO, USA). After 18 h, cells were pulsed with BrdU for 5 h and then 
TUNEL assay
At 16 days after inoculation with TE3 parent cells, TE3-MAL expressing tumor cells or TE3-MAL nonexpressing tumor cells, the mice were killed and the tumor specimens were stored at À201C. The samples were cut and processed for hematoxylin-eosine and apoptosis staining (ApopTag Peroxidase Kits, Intergen Company, NY, USA) according to the manufacturer's instructions.
In brief, after the specimens were rinsed with PBS and digested with proteinase-K (20 mg/ml), 75 ml of equilibration buffer was immediately applied directly to the slides. Working strength TdT enzyme (55 ml/5 cm 2 ) was pipetted onto the section and incubated in a humidified chamber at 371C. The specimens were put in a Coplin jar containing working strength stop/wash buffer, agitated for 15 s, and incubated for 10 min at room temperature. After antidigoxigenin peroxidase conjugate (65 ml/5 cm 2 ) was applied to the slides and allowed to incubate for 30 min at room temperature, the slides were washed in four changes of PBS for 2 min at room temperature. Peroxidase substrate was applied to the specimens for 5 min, and then the slides were counterstained in 0.5% methyl green in a Coplin jar for 10 min at room temperature.
